Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:
Appears in 8 contracts
Samples: Option and License Agreement, Option and License Agreement (Ultragenyx Pharmaceutical Inc.), Option and License Agreement (Dimension Therapeutics, Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country basisbasis when all Valid Claims in that country claiming the Licensed Product have expired, as follows:lapsed, been abandoned, or been invalidated.
Appears in 4 contracts
Samples: License Agreement (Audentes Therapeutics, Inc.), License Agreement (Audentes Therapeutics, Inc.), License Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:basis when ****.
Appears in 3 contracts
Samples: License Agreement (REGENXBIO Inc.), License Agreement (REGENXBIO Inc.), License Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 3.3 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:basis […***…].
Appears in 3 contracts
Samples: License Agreement (Ultragenyx Pharmaceutical Inc.), License Agreement (Dimension Therapeutics, Inc.), License Agreement (Dimension Therapeutics, Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:basis when the Licensed Product ceases to infringe or be covered by a Valid Claim in that country.
Appears in 3 contracts
Samples: License Agreement (AveXis, Inc.), License Agreement (AveXis, Inc.), License Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country basiscountry, as follows:Licensed Product-by-Licensed Product basis on the later of: (i) expiration, lapse, abandonment, or invalidation of the last Valid Claim of the Licensed Patents to expire, lapse, become abandoned or become unenforceable for the applicable Licensed Product in the applicable country, or (ii) **** from the First Commercial Sale of the applicable Licensed Product in the applicable country.
Appears in 2 contracts
Samples: License Agreement (Abeona Therapeutics Inc.), License Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 3.3 on the Net Sales of Licensed Products in a given country will end on a country-by-country basisbasis when all Valid Claims in that country claiming the Licensed Product have expired, as follows:lapsed, been abandoned, or been invalidated.
Appears in 2 contracts
Samples: License Agreement (REGENXBIO Inc.), License Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 3.3.1 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:by country basis when there is no Valid Claim in that country claiming the Licensed Product.
Appears in 1 contract
Samples: Confidential Treatment Requested Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 3.3.1 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:by country basis when ****.
Appears in 1 contract
Samples: Confidential Treatment Requested Agreement (REGENXBIO Inc.)
Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.4 3.3 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis, as follows:basis ****.
Appears in 1 contract
Samples: License Agreement (REGENXBIO Inc.)